Tacrolimus and Emphysematous cholecystitis - a phase IV clinical study of FDA data

Summary:

Emphysematous cholecystitis is reported as a side effect among people who take Tacrolimus (tacrolimus), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Cyclophosphamide, and have Acute graft versus host disease.

The phase IV clinical study analyzes which people have Emphysematous cholecystitis when taking Tacrolimus. It is created by eHealthMe based on reports of 115,828 people who have side effects when taking Tacrolimus from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Emphysematous cholecystitis?

Emphysematous cholecystitis (acute infection of the gallbladder wall caused by gas-forming organisms) is found to be associated with 7 drugs and 36 conditions by eHealthMe. Check the latest studies of Emphysematous cholecystitis.

On Jul, 29, 2026

115,828 people reported to have side effects when taking Tacrolimus.
Among them, 15 people (0.01%) have Emphysematous cholecystitis.

Could Tacrolimus cause Emphysematous cholecystitis?

Among these 15 people:

How long have people been on Tacrolimus when they have Emphysematous cholecystitis? *

What is the gender of people who have Emphysematous cholecystitis when taking Tacrolimus? *

female: 35.71 %
male: 64.29 %

What is the age of people who have Emphysematous cholecystitis when taking Tacrolimus? *

What are other drugs people take besides Tacrolimus? *

What are other side effects people have besides Emphysematous cholecystitis? *

Systemic Candida (whole body fungal infection): 5 people, 33.33%
Septic Shock (shock due to blood infection): 5 people, 33.33%
Pancreatitis (inflammation of pancreas): 5 people, 33.33%
Clostridial Infection (infectious conditions by clostridium bacteria): 5 people, 33.33%
Cholangitis Sclerosing (infection and obstruction of bile duct): 5 people, 33.33%
Swallowing Difficulty: 3 people, 20.00%
Immunosuppressant Drug Level Increased: 3 people, 20.00%
Pvt: 2 people, 13.33%
Portal Vein Phlebitis (inflammation of a hepatic portal vein): 2 people, 13.33%
Cholangitis (infection of the bile duct): 2 people, 13.33%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 5 people, 33.33%
Bone Marrow Conditioning Regimen: 5 people, 33.33%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 33.33%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 5 people, 33.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 20.00%
Fever: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and have Emphysematous cholecystitis?

- Check whether Emphysematous cholecystitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tacrolimus:

Tacrolimus (116,160 reports)

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Emphysematous cholecystitis:

Emphysematous cholecystitis (8 drugs)

Browse all the conditions that are associated with Emphysematous cholecystitis:

Emphysematous cholecystitis (36 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Tacrolimus) and Tacrolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.